Skip to content

Congratulations to Clinical Psychology Ph.D. student, Andrew Barnett and colleagues on a forthcoming article that has been accepted for publication in the American Psychologist. Co-authors include current program students Ben Parchem & Veronica Pinho, Applied Social Psychology Ph.D. alumna Ana Maria del Rio-Gonzalez, Clinical Psychology Ph.D. alumae Rodrigo Aguayo-Romero & Nadine Nakamura, Clinical Psychology faculty Maria Cecilia Zea and Sarah Calabrese, and Applied Social Psychology faculty Paul Poppen.

The article will be published as a part of a special issue that will focus on the science and history of sexual orientation and gender diversity. Full reference:

Barnett, A.P., del Rio-Gonzalez, A.M., Parchem, B., Pinho, V., Aguayo-Romero, R., Nakamura, N., Calabrese, S.K., Poppen, P.J., and Zea, M.C. (in press). Content Analysis of Psychological Research with Lesbian, Gay, Bisexual, and Transgender People of Color in the United States: 1969–2018. American Psychologist.

Congratulations on this great team effort!

Stigma may keep women from using HIV-prevention drugs

Originally posted on Reuters 6/14/18: https://in.reuters.com/article/us-health-women-hiv-prevention/stigma-may-keep-women-from-using-hiv-prevention-drugs-idINKBN1JA2ZO

(This June 14 story revises paragraph 2 to correct the number of women using PReP; revises paragraph 11 to remove a reference to a video that wasn’t part of the study.)

By Shereen Lehman

(Reuters Health) - Fear of others thinking they’re promiscuous, or that they’re already infected with HIV, is a barrier to many women who might benefit from pills that help prevent the infection, a U.S. study suggests.

About 200,000 U.S. women are thought to be strong candidates for HIV pre-exposure prophylaxis, or PrEP, but only about 50,000 have ever used the pills and only about 3,000 are presently using them, the study team writes in Journal of Acquired Immune Deficiency Syndrome.

“Negative social attitudes about PrEP, including stereotypes about PrEP users, have the potential to discourage women from considering PrEP as an option for themselves,” lead author Sarah Calabrese, a psychology researcher at George Washington University in Washington, D.C., told Reuters Health in an email.

“It is important for us to understand women’s negative attitudes about PrEP so that we can correct misperceptions and promote a more positive image of PrEP.”

The study, part of a larger project aimed at optimizing PrEP service delivery at Planned Parenthood, explored stigma as a potential barrier to PrEP use by women because early focus group research had suggested this may be an issue, Calabrese noted.

“Currently, there is one form of PrEP available in the U.S.: a once-a-day pill. When taken as prescribed, it can be over 90 percent effective in preventing HIV,” she said.

One reason that PrEP is an especially exciting option for women is that they can use it to protect themselves from HIV without the knowledge or consent of their sexual partners, Calabrese said.

“Some women may decide that PrEP is not for them, but all women should at least know about it so that they have the opportunity to make that decision,” Calabrese said.

GW is committed to digital accessibility. If you experience a barrier that affects your ability to access content on this page, let us know via the Accessibility Feedback Form.